Potential nanotherapeutic strategies for perioperative stroke

Jingyi An1,2,3 | Ling Zhao1 | Ranran Duan4 | Ke Sun5 | Wenxin Lu1 | Jiali Yang1 | Yan Liang1 | Junjie Liu1,2,3 | Zhenzhong Zhang1,2,3 | Li Li6 | Jinjin Shi1,2,3

Abstract

Aims: Based on the complex pathological environment of perioperative stroke, the development of targeted therapeutic strategies is important to control the development of perioperative stroke.

Discussions: Recently, great progress has been made in nanotechnology, and nanodrug delivery systems have been developed for the treatment of ischemic stroke.

Conclusion: In this review, the pathological processes and mechanisms of ischemic stroke during perioperative stroke onset were systematically sorted. As a potential treatment strategy for perioperative stroke, the review also summarizes the multifunctional nanodelivery systems based on ischemic stroke, thus providing insight into the nanotherapeutic strategies for perioperative stroke.

KEYWORDS
anti-inflammatory, antioxidant, nanodelivery system, neuronal regeneration, perioperative stroke, thrombolysis

With the advent of “global aging,” stroke has become the world’s second-deadliest disease after coronary heart disease, accounting for 10%–15% of global deaths.1–3 The perioperative period can be a high-risk period for stroke because of the pathophysiological state of the patient, which is based on the disease, anesthesia, functional changes in the coagulation system and pharmacological factors.4–6 Recently, the number of patients with perioperative acute ischemic stroke (PAIS) has increased significantly.7 Regrettably, clinical approval for the prevention and treatment of perioperative ischemic stroke has not yet been obtained.8 Therefore, the development of more therapeutic strategies for perioperative stroke is urgently needed.9,10 Given the similar pathophysiology of perioperative stroke...
strokes and simple stroke, nanotherapeutic strategies for simple stroke are also potential for the treatment of perioperative stroke. Therefore, the current nanotherapeutic strategies for simple stroke are summarized to provide insight into the nanotherapeutic strategies for perioperative stroke.

1 | DEFINITION AND CLASSIFICATION OF PERIOPERATIVE STROKE

The World Health Organization (WHO) defines perioperative stroke as a focal or diffuse cerebral neurological deficit caused by intraoperative or postoperative cerebrovascular etiology, which can last up to 24 h or result in death within 24 h of occurrence. Based on perioperative stroke data, hemorrhagic strokes account for 1%–4% of strokes, and perioperative strokes are predominantly embolic.11 The mechanism of embolism in perioperative stroke is not well understood and may be related to the following factors (Table 1).

2 | MORBIDITY AND MORTALITY

A recent retrospective analysis, including 370,000 perioperative stroke patients, found the incidence of ischemic stroke to be 0.7% after a partial colectomy, 0.2% after a total hip replacement, 0.2% after a pulmonary surgery, 2.2%–5.2% after neurosurgery, and up to 2%–10% after cardiac and microvascular surgery.18,19 The risk of PAIS in the elderly population increases with age,19 from 0.1%–0.2% under 65 years of age to 0.5% between 65 and 74 years of age, and 1.0% over 75 years of age.20,21 Despite current improvements in surgical techniques and surgical treatments, the incidence of perioperative strokes has not decreased significantly, increasing to 0.8% in patients undergoing non-cardiac major vascular surgery. The mortality rate of perioperative strokes is 18%–26% higher compared with non-operative stroke patients.22

3 | RISK FACTORS

Perioperative stroke is associated with multiple risk factors, as detailed in Table 2

4 | PATHOPHYSIOLOGY OF PERIOPERATIVE STROKES

Perioperative stroke is dominated by ischemia and embolism. In an ischemic stroke, vascular occlusion leads to the disorders of local blood supply in the corresponding brain regions,23 which induces a complex series of cascade reactions at the (sub)cellular and molecular levels,24,25 and ultimately leads to cellular and tissue damage.26–28 The pathological biochemical reaction of an ischemic stroke begins with energy deprivation induced by a lack of oxygen and glucose supply to local brain tissue,29,30 This is followed by stimulation of neuronal depolarization and glutamate release, causing calcium inward flow and elevated sodium ion content in the intracytoplasmic, and more glutamate release which leads to cellular excitotoxicity and cellular swelling,31 ion channel dysfunction, and massive reactive oxygen and/or nitrogen species, ROS/RNS or RONS production.32

These pathological and biochemical changes at the cellular and molecular levels further spread to neighboring cells, activating a series of enzymatic cascade reactions that eventually lead to the cell membrane and mitochondrial damage and production of RONS33,34; the production of RONS can further damage mitochondria and DNA, eventually leading to cellular necrosis or apoptosis.35–38 Inflammatory mediators or cytokines secreted by necrotic or apoptotic cells activate resting microglia in the brain and promote the invasion and infiltration of peripheral neutrophils and macrophages39,40; activated microglia in the brain can further converge and aggregate toward damaged neurons,41 mediating the release of pro-inflammatory factors, and start a vicious circle, aggravating neural damage.42–45

5 | POTENTIAL NANTHERAPEUTIC STRATEGIES FOR PERIOPERATIVE STROKE

Nanotechnology is the science and technology of making substances from individual atoms and molecules, and it studies the properties and applications of materials with structural dimensions in the range of 1-100 nanometers.46,47 Nanotechnology has developed rapidly in the last few decades and shows potential in the diagnosis and treatment of diseases.48–50 The properties of nanomaterials differ

---

TABLE 1   Possible mechanisms for the occurrence of ischemic stroke during perioperative procedures

| Mechanism                           | Content                                      | Authors & Year |
|-------------------------------------|----------------------------------------------|----------------|
| Thrombus shedding                   | Heart-borne thrombosis sheds and reaches the brain with the blood flow | Maida CD,12 2020 |
| Brain local low perfusion           | Chronic hypertension, diabetes, geriatric atherosclerosis, and other factors leading to vascular stenosis | Campbell BC,13 2019 |
|                                      | Low blood pressure and slow blood flow during surgery for a long time | Kam PCA,14 1997 |
|                                      | Surgical trauma or tissue damage causing increased blood viscosity | Bijker JB,15 2013 |
| Sudden fluctuations in blood pressure | Surgery and anesthetic stimulation causing blood pressure to rise or drop sharply | Anadani M,16 2021 |
| Embolism                            | Fat, air, or cancer embolism                 | Keller K,17 2020 |
Nanotechnology provides a convenient platform for immobilizing and loading specific molecules or drugs on nanocarriers at higher loading rates. Nanomedicines also possess unique advantages in the development of drug strategies to penetrate the blood–brain barrier (BBB) by surface-functionalized ligand modifications that target and penetrate the BBB and increase its half-life in the blood circulation. The passive/active targeting properties and improvement of the biostability of neurotherapeutic drugs increase the drug concentration in the pathological injury zone to achieve the desired therapeutic effect. Nanomaterials are also a good alternative for developing drug strategies to penetrate the blood–brain barrier (BBB) by surface-functionalized ligand modifications that target and penetrate the BBB and increase its half-life in the blood circulation. The passive/active targeting properties and improvement of the biostability of neurotherapeutic drugs increase the drug concentration in the pathological injury zone to achieve the desired therapeutic effect. Nanomaterials have a great potential for biomarker development, disease diagnosis, and disease treatment, which are as follows: targeting damaged cells or tissues through molecular-scale interactions with improved and modified nanomaterials; controlled release of drugs by nano-engineered materials, improving bioavailability, transporting multiple drug formulations, and protecting drug compounds from degradation through different molecular modifications on the surface. Nanomaterials are also a good alternative for developing drug strategies to penetrate the blood–brain barrier (BBB) by surface-functionalized ligand modifications that target and penetrate the BBB and increase its half-life in the blood circulation. The passive/active targeting properties and improvement of the biostability of neurotherapeutic drugs increase the drug concentration in the pathological injury zone to achieve the desired therapeutic effect. Nanotechnology provides a convenient platform for immobilizing and loading specific molecules or drugs on nanocarriers at higher loading rates. Nanomedicines also possess neuroprotective effects. These properties of nanomaterials place them at the forefront of future precision diagnosis and treatment of central nervous system diseases, such as ischemic stroke.

Nanodrug delivery systems have unique advantages in the treatment of ischemic stroke, including enhanced BBB permeability, targeting, and modulating drug release. Most studies on nanotechnology-based therapies for ischemic stroke have focused on targeting revascularization, antioxidative stress, inflammation, and apoptosis, and promoting neuronal regeneration as shown in Table 3.

### 5.1 Nanodelivery strategies for revascularization

Currently, tissue plasminogen activator (tPA) intravenous thrombolysis remains the standard clinical treatment for patients with acute ischemic stroke within 4–5 h after the onset of ischemic stroke. However, due to the limited “therapeutic window,” only a minority of patients (<10%) receive this treatment. To broaden the therapeutic window of tPA, Mei et al. designed a t-PA-installed, nitroxide radical-containing, self-assembled polyion complex nanoparticles (t-PA@iRNP). This improved pharmacological performance of t-PA@iRNP prevented the rapid metabolism and excretion out of the body after systemic circulation, thus remarkably extending the in vivo half-life of t-PA. Marianna et al. constructed a nanoagent by directly combining the clinical formulation of tPA with the porous structure of soft discoidal polymer nanostructures (TPA-DPNs) (Figure 1A). Due to the protective effect of the porous matrix in DPNs, tPA degrades slowly in serum, and TPA-DPNs retained more than 70% of its original activity after 3 h of exposure to serum protein (Figure 1B).

Ischemic stroke slows the blood flow by vascular obstruction and higher doses of tPA are needed for effective thrombolytic therapy, which may result in cerebral edema and cerebral hemorrhage. To improve the thrombolytic effect, Wang et al. designed a nanodelivery system based on gold@mesoporous silica core-shell nanospheres (Au@MSNs) (Figure 2A), which uses a near-infrared (NIR) laser (808 nm) to trigger the release of tPA. tPA is encapsulated with the phase change material 1-tetradecanol (Tet) into the pore of Au@MSNs. Laser irradiation is expected to release tPA from the nanocarrier when 1-tetradecanol is reconverted to liquid due to the photothermal conversion of gold (Figure 2B). The photothermal-only treatment group also has a thrombolytic effect (Figure 2C,D). The tPA-NPs achieved targeted release of tPA and enhanced the thermotherapeutic thrombolytic effect locally on NIR laser irradiation. Further, ultrasound energy enhanced the efficacy of thrombolytic drugs. Daffertshofer et al. showed that ultrasonic waves at 300-KHZ penetrated the bone efficiently and exposed the entire brain to ultrasound. However, there was a 36% hemorrhage rate in the group treated with rt-PA plus ultrasound. Focused ultrasound of the Willis circle, with or without microbubbles, appears to be a promising...
| Nanotherapeutic strategies | Carrier type/materials | Drug(s) delivered | Major findings and comments | Authors & Year |
|---------------------------|------------------------|-------------------|----------------------------|----------------|
| Revascularization         | Antioxidant nanoparticles | t-PA             | Extended the in vivo half-life of t-PA in systemic circulation, improved its bioavailability, and extended therapeutic window | Mei T,83 2019 |
|                           | Soft discoidal polymeric | t-PA             | Preserved lytic activity, the deforming ability, and blood circulating time, together with the faster blood clot dissolution | Colasuonno M,84 2018 |
|                           | gold@mesoporous silica core–shell nanospheres | uPA             | A near-infrared-triggered controlled release on demand, hyperthermia-enhanced thrombolysis locally for decreasing drug dosage | Wang X,85 2017 |
|                           | Mesoporous/macroporous silica (MMSI/platinum (Pt) nanomotor (MMNM) coated with platelet membrane (PM)) | Urokinase/Hep | The motility of the nanomotor can effectively facilitate its deep penetration into the thrombus site and improve retention | Wan M,86 2020 |
|                           | Polymeric nanoparticles wrapped with membranes platelet membrane cloaked polymeric nanoparticles (PNP-PA) | Alendronate sodium | Enhanced drug accumulation at skeletal sites and reduced off-target effects | Matrali SSH,87 2020 |
|                           | Polymeric nanoparticles wrapped with membranes platelet membrane cloaked polymeric nanoparticles (PNP-PA) | t-PA             | PNP-PA exhibited potent innate targeting and local clot degradation with a low risk of bleeding complications | Xu J,88 2020 |
| Scavenging reactive oxygen species | CeO2 nanoparticles | ZIF-8          | Exhibits prolonged blood circulation time, reduced clearance rate, improved BBB penetration ability, and enhanced brain accumulation | He L,89 2020 |
|                           | Framework nucleic acid | Anti-C5a aptamers | Selectively reduce C5a-mediated neurotoxicity and effectively alleviate oxidative stress in the brain | Li S,90 2019 |
|                           | Polyoxometalate nanoclusters | Mo             | Excellent scavenging activity of ROS by changing their reduced and oxidized status | Li S,91 2019 |
| Anti-inflammation          | Liposomal              | 9-aminoacridine (9-AA) | Liposomal 9-AA can efficiently encapsulate 9-AA, exhibit anti-inflammatory activities through an NR4A1/IL-10/ SOCS3 signaling pathway and modulate the microglia activation | Wang H,92 2020 |
|                           | ROS-responsive and fibrin-binding polymers micelle | Rapamycin     | The combination of micelle facilitated ROS elimination and anti-stress signaling pathway interference under ischemia conditions | Lu Y,93 2019 |
|                           | Platelet-mimetic nanoparticles (PTPNPs) co-loaded with piceatannol | Piceatannol     | Decrease neutrophil infiltration and reduce infarct size, monitor the inflammatory neutrophils coupled with magnetic resonance imaging | Tang C,94 2019 |
means of improving the efficacy of intravenous thrombolytic drugs. A larger phase III trial is currently being tested. 101

Tissue plasminogen activator activation of fibrinolytic is systemic and does not target specific regions for fibrin activation. To improve the accuracy of tPA thrombolysis, Wan et al. 86 designed a mesoporous/macroporous silica (MMS)/platinum (Pt) nanomotor (MMNM) coated with platelet membrane (PM) (called MMNM/PM). The large-sized thrombolytic drug urokinase was loaded into the nanomotor’s macroporous structure and the anticoagulant drug Hep was loaded into the mesoporous structure. Regulated by a special protein on the PM, the nanomotor targeted the thrombus site, and then, the PM was fractured on NIR irradiation and rapidly released thrombolytic urokinase (3 h) and sustained release of anticoagulant heparin (>20 days), sequentially releasing two drugs. Meanwhile, the motility of the nanomotor under NIR irradiation effectively facilitated its deep penetration into the thrombus site and improved retention. Hu et al. 87 also constructed a nanocarrier with a bone-targeted core–shell structure in which platelet membranes were wrapped around the surface of polymeric nanoparticles. Alendronate sodium (Ald) is used as a targeted ligand for its ability to chelate calcium ions in the bone microenvironment, enhancing drug accumulation at the skeletal site and reducing off-target effects. Xu et al. 102 developed platelet membrane cloaked polymeric nanoparticles (PNP) conjugated with rt-PA on the surface to achieve clotting targeting thrombolytic therapy. PTP-PA exhibited strong innate targeting and local clot degradation after intravenous administration in different animal models of thrombus, including mesenteric artery embolism, PE, and ischemic stroke, indicating the excellent therapeutic potential in a broad spectrum of thrombo-related diseases. These innovative nanotechnologies open up new avenues for tPA-based stroke therapy.

5.2 | Nanodelivery strategies for scavenging reactive oxygen species

Recent advances in nanomedicine have facilitated the development of functional nanomaterials, such as carbon, vanadium, manganese, platinum, and cerium nanoparticles with higher antioxidant activity and stability than natural enzymes. 103,104 Liu et al. 75 revealed the detailed mechanism of the antioxidant effect of water-soluble MeNPs by comprehensively analyzing their scavenging activity against a variety of RONS. The results showed that PEG-MeNPs had a catalytic mechanism for O₂⁻ that mimicked SOD. Compared with natural antioxidant enzymes (e.g. SOD), the nano-antioxidants targeted specific RONS, PEG-MeNPs and exhibited a wide range of antioxidant activities against a variety of toxic RONS, including -OH, O₂⁻, H₂O₂, ·NO, and ONOO⁻, highlighting the strong scavenging capacity of reactive oxygen species by nano-antioxidants. In vitro experiments showed that PEG-MeNPs have neuroprotective and anti-inflammatory effects. In vivo results further demonstrated that MeNPs have a unique combination of antioxidant, anti-inflammatory, and biocompatibility, which effectively protects against ischemic brain injury with negligible side effects. A new strategy for the in situ synthesis of ZIF-8-covered CeO₂ NPs (CeO₂@ZIF-8) was explored by He et al. 89 The surface ZIF-8 acted as a peroxidase that maintained antioxidant activity in the presence of excess H₂O₂ or other oxidants and absorbed H₂O₂ and broke O–O bonds to decompose H₂O₂ with enhanced catalytic and antioxidant activities.

Furthermore, it has been shown that ischemic stroke triggers activation of the complement system, leading to an increase in aC5a in plasma and ischemic penumbra, triggering an inflammatory cascade response and exacerbating the vicious cycle between oxidative stress and inflammatory responses. Li et al. 90 prepared a bipyramidal FNA

| TABLE 3 (Continued) |
| Nanotherapeutic strategies | Carrier type/materials | Drug(s) delivered | Major findings and comments | Authors & Year |
| Neuronal regeneration | Degradable nanomaterials | CAT/SOD | Provide a good microenvironment for neural progenitor cell activation and migration after cerebral infarction and promote endogenous neuronal regeneration | Petro M. 95 2016 |
| Magnetosome-like ferrimagnetic iron oxide nanochains (MFIONs) | DNA/PEI | Ferrimagnetic nanochains-based mesenchymal stem cell engineering augment the homing ability of the engineered MSCs to the ischemic cerebrum for highly efficient post-stroke recovery | Zhang T. 96 2019 |
| Magnetic nano-vesicles (MNV) | Iron oxide nanoparticles (IONP) | Promoted the anti-inflammatory response, angiogenesis, and anti-apoptosis in the ischemic brain lesion, thereby yielding a considerably decreased infarction volume and improved motor function | Kim HY. 97 2020 |
loaded with C5a aptamers (aC5a-FNA) (Figure 3). After intrathecal injection, aC5A-FNA selectively alleviated C5A-mediated neurotoxicity and effectively relieved oxidative stress in the brain. Another study also showed that ultra-small molybdenum polyoxometalate nano-clusters (POM) had excellent ROS scavenging capability by changing their reduction and oxidation states. After intrathecal injection, POM nanoclusters were preferentially uptake by the brain, leading to rapid accumulation of POM nanoclusters in the ischemic penumbra, alleviating oxidative stress and inflammatory injury, effectively inhibiting neuronal apoptosis after brain I/R injury, and restoring neuronal function.

5.3 | Nanodelivery strategies for anti-inflammation

The acute systemic inflammation induced by surgery induces or exacerbates ischemic brain injury. The inflammatory response has important implications for stroke susceptibility and prognosis and is involved in the pathophysiological process of stroke. During this process, TNF-α, IL-1, IL-6, and C-reactive protein levels are significantly increased. They activate microglia in the brain and stimulate invasive infiltration of peripheral leukocytes, thus accelerating ischemic damage and expanding the infarct area. Therefore, blocking the inflammatory response to alleviate injury is an extremely promising neuroprotective therapeutic strategy. Wang et al. found that 9-AA can act as a novel NR4A1 activator to downregulate the activation levels of microglia and macrophages through the NR4A1/IL-10/SOCS3 signaling pathway to mitigate inflammatory responses. However, the low therapeutic index and poor water solubility of 9-AA greatly limit its application in vivo. To avoid the adverse effects of 9-AA, they prepared a PEG/cRGD double-modified liposome loaded with 9-AA, which prolonged its blood circulation, and significantly reduced its side effects on the lung.

mTOR inhibitors have been reported to reduce neuroinflammation and reperfusion injury by polarizing microglia from pro-inflammatory M1 type to anti-inflammatory M2 type. In addition, inhibition of the mTOR pathway induced autophagy and removed damaged organelles to repair neurons. Lu et al. developed a polymer micellar system with neurovascular targeting and mTOR...
inhibition. Briefly, the mTOR inhibitor rapamycin was encapsulated in micelles formed by self-assembly of fibrin-binding peptide (CREKA) and reactive oxygen scavenging polymer (C-PEG-Lysb). In vivo results confirmed that the micelles enriched in ischemic sites and achieved the controlled release of drugs, induced the elimination of ROS, reshaped the phenotype of microglia, and alleviated neurovascular injury caused by oxidative stress; they also enhanced blood perfusion and neuroprotection.

Neutrophils autonomously migrate to the ischemic zone and release reactive oxygen species after receiving inflammatory signals during stroke, which is considered to be the main cause of reperfusion injury after AIS. Therefore, reducing inflammatory neutrophil infiltration may be an effective treatment for AIS. Based on the specific affinity between inflammatory neutrophils and activated platelets, Tang and other colleagues designed platelet-mimetic nanoparticles (PTNPs) that directly identified, intervened, and monitored activated neutrophils during inflammation (Figure 4A). After intravenous injection, PTNPs selectively recognize inflammatory neutrophils via a specific affinity between p-selectin and the pskl-1 microregion. PTNPs were then internalized into adherent neutrophils where the loaded piceatannol was released, thus promoting the detachment of neutrophils from endothelial cells into circulation, resulting in decreased neutrophil infiltration (Figure 4B). In vivo results showed that this bionic strategy reduced inflammatory infiltration of neutrophils, decreased infarct volume, and improved the neurological function of ischemic stroke.

5.4 | Nanodelivery strategies for neuronal regeneration

Ischemic stroke can present with impairment or loss of neuronal regenerative capacity, progressively causing impaired neuronal function or structural changes. Thus, improving neuronal regenerative capacity has potential in the treatment of ischemic stroke. Petro, M and other colleagues injected tPA into the carotid artery 3 h after ischemic stroke for post-ischemic reperfusion, followed by immediate injection of degradable nanomaterials (nano-CAT/SOD) encapsulated with antioxidants CAT and SOD. The results showed that the nano-CAT/SOD group presented more neuronal cells in the brain of ischemic stroke rats, and neuronal cells migrated from

FIGURE 3  Schematic of cerebral ischemia-reperfusion injury (IRI) treatment using an anticomplement component 5a (aC5a) loaded framework nucleic acid (aC5a-FNA) after intrathecal injection. PET imaging and brain tissue staining confirmed the biodistribution and treatment efficacy of FNA for brain IRI management. Reprinted (adapted) with permission from Ref. [90]. Copyright 2019 American Chemical Society

FIGURE 4  (A) A diagram of the main components of PTNPs. (B) Schematic of PTNPs reducing inflammatory neutrophil infiltration. Reprinted (adapted) with permission from Ref. [94]. Copyright 2019 American Chemical Society
the subventricular layer of the lateral ventricle into the anastomotic lateral flow, and nano-CAT/SOD reduced neutrophil infiltration in the brain and inhibited neuronal cell apoptosis. This suggests that nano-CAT/SOD may provide a good microenvironment for neural progenitor cell activation and migration after cerebral infarction and promote endogenous neuronal regeneration. Some growth factors such as erythropoietin, epidermal growth factor, nerve growth factor, and brain-derived neurotrophic factor have been found to stimulate neuronal regeneration. Zhang et al.96 designed multimeric nanoparticles containing epidermal growth factor (to stimulate neural stem/progenitor cell proliferation) or erythropoietin (to reduce neonatal apoptosis).

In addition, Han97 demonstrated that magnetic NV (MNV) derived from MSCs containing iron oxide nanoparticles (IONP) improved targeting and therapeutic efficacy to ischemic lesions (Figure 5). Because IONP stimulates the expression of therapeutic growth factors in MSCs, MNV contains more of these therapeutic molecules compared to NV derived from innocent MSCs. In a transient middle cerebral artery occlusion (MCAO) rat model, the magnetic navigation increased the localization of MNV to ischemic lesions by 5.1-fold after systemic injection of MNV. Injection of MNV and magnetic navigation promoted anti-inflammatory responses, angiogenesis, and anti-apoptosis in ischemic brain lesions, resulting in a significant reduction in infarct volume, and improved motor function.

In conclusion, the ideal stroke treatment should be beneficial in antagonizing both primary and secondary neuronal damage caused by an ischemic stroke. Theoretically, combined therapies that alleviate early ischemic-hypoxic injury may provide durable neuronal protection, and promote neuronal regeneration in ischemic stroke, and may be beneficial in expanding the therapeutic time window, minimizing drug side effects, and maximizing the intensity of the ischemia/reperfusion-induced neuronal injury.

6 | FUTURE PERSPECTIVES

In the last decades, nanotechnology has made great contributions to the treatment of ischemic stroke. Compared with traditional treatment methods, nano-formulations and nanodrug delivery systems have significant advantages in improving drug penetration into the BBB, increasing drug bioavailability, and maintaining and controlling drug release. However, as an emerging technology, safety issues such as the biocompatibility of nanotechnology still exist, and technical improvements are still needed. Most of the nanotechnology-based ischemic stroke diagnostic and therapeutic applications are still at the preclinical stage, and further clinical data are lacking to facilitate their clinical translation. This review focuses on the bioavailability, biosafety, biodegradation, and specific targeting of nanomedicines and nanodrug delivery systems, which is the key to the translation of nanomedicines from bench to bedside. It is necessary to optimize the size, structure, function, physicochemical properties and other parameters of nanoparticles to make them efficient nanomedicines or drug carriers with low side effects. Soon, nanotechnology may become an effective diagnostic and therapeutic tool for ischemic stroke, and even both. With the rapid development of nanomedicine and in-depth study of stroke mechanisms, nanotechnology will play an important role in the clinical application of stroke.

CONFLICTS OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTION

JYA drafted the manuscript. RRD and KS searched for relevant literature and were responsible for the major revisions. JJS and
REFERENCES

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. *Lancet Neurol.* 2007;6(2):182-187.

2. Gorelick PB, Whelton PK, Sorond F, et al. Blood pressure management in stroke. *Hypertension.* 2020;76(6):1688-1695.

3. Gervois P, Wolfs E, Ratajczak J, et al. Stem cell-based therapies for ischemic stroke: preclinical results and the potential of imaging-assisted evaluation of donor cell fate and mechanisms of brain regeneration. *Med Res Rev.* 2016;36(6):1080-1126.

4. Limburg M, Wijdicks EFM, Li H. Ischemic stroke after surgical procedures. *Neurology.* 1998;50(4):895.

5. Salehi MS, Pandamooz S, Safari A, et al. Exosomes from miRNA-126-modified endothelial progenitor cells alleviate brain injury and promote functional recovery after stroke. *CNS Neurosci Ther.* 2020;26(12):1255-1265.

6. Maida CD, Norrito RL, Daidone M, et al. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. *Int J Mol Sci.* 2020;21(18):6454.

7. Meschia JF, Brott T. Ischaemic stroke. *Eur J Neurol.* 2018;25(1):35-40.

8. Kam PCA, Calcroft RM. Peri-operative stroke in general surgical patients. *Anaesthesia.* 1997;52(9):879-883.

9. Bijker JB, Gelb AW. Review article: the role of hypotension in perioperative stroke. *Can J Anaesth.* 2013;60(2):159-167.

10. Anadani M, Matusevicius M, Tsivgoulis G, et al. Magnitude of blood pressure change and clinical outcomes after thrombectomy in stroke caused by large artery occlusion. *Eur J Neurol.* 2021;28(6):1922-1930.

11. Wang J, Chen S, Zhang W, et al. Exosomes from miRNA-126-modified endothelial progenitor cells alleviate brain injury and promote functional recovery after stroke. *CNS Neurosci Ther.* 2020;26(12):1255-1265.

12. George A, Mashour MS, Robert E, et al. Perioperative metoprolol and risk of stroke after noncardiac surgery. *Anesthesiology.* 2013;119:1340-1346.

13. Maida CD, Norrito RL, Daidone M, et al. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. *Int J Mol Sci.* 2020;21(18):6454.

14. Kam PCA, Calcroft RM. Perioperative stroke in general surgical patients. *Anaesthesia.* 1997;52(9):879-883.

15. Bijker JB, Gelb AW. Review article: the role of hypotension in perioperative stroke. *Can J Anaesth.* 2013;60(2):159-167.

16. Anadani M, Matusevicius M, Tsivgoulis G, et al. Magnitude of blood pressure change and clinical outcomes after thrombectomy in stroke caused by large artery occlusion. *Eur J Neurol.* 2021;28(6):1922-1930.

17. Keller K, Hobohm L, Munzel T, et al. Impact of pulmonary embolism on in-hospital mortality of patients with ischemic stroke. *J Neurol Sci.* 2020;419:117174.

18. Bateman BT, Schumacher HC, Wang S, et al. Perioperative acute ischemic stroke in noncardiac and nonvascular surgery. *Perioper Med.* 2009;10:231-238.

19. Zhao J, Liu R. Promoting stroke awareness through short movies and film festivals. *CNS Neurosci Ther.* 2021;27(9):991-993.

20. Kikura M, Oikawa F, Yamamoto K, et al. Myocardial infarction and cerebrovascular accident following non-cardiac surgery: differences in postoperative temporal distribution and risk factors. *J Thromb Haemost.* 2008;6(5):742-748.

21. Merie C, Kober L, Olsen PS, et al. Risk of stroke after coronary artery bypass grafting: effect of age and comorbidities. *Stroke.* 2012;43(1):38-43.

22. Kikura M, Bateman BT, Tanaka KA. Perioperative ischemic stroke in non-cardiovascular surgery patients. *J Anesth.* 2010;24(5):733-738.

23. Sanders RD, Grocott HP. Perioperative stroke: time to redefine the impact of age? *Stroke.* 2012;43(1):3-5.

24. Bejot Y, Duloquin G, Crespy V, et al. Influence of preexisting cognitive impairment on clinical severity of ischemic stroke: the Dijon stroke registry. *Stroke.* 2020;51(6):1667-1673.

25. Bushnell CD. *Stroke* and the female brain. *Nat Clin Pract Neurol.* 2008;4(1):22-33.

26. Hu J, Lin JH, Jimenez MC, et al. Plasma estradiol and testosterone levels and ischemic stroke in postmenopausal women. *Stroke.* 2020;51(4):1297-1300.

27. Go AS, Reynolds K, Yang J, et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. *JAMA Cardiol.* 2018;3(7):601-608.

28. Khurshid S, Trinquart L, Weng LC, et al. Atrial fibrillation risk and discrimination of cardioembolic from noncardioembolic stroke. *Stroke.* 2020;51(5):1396-1403.

29. Asenbaum U, Nolz R, Puchner SB, et al. Coronary artery bypass grafting and perioperative stroke: imaging of atherosclerotic plaques in the ascending aorta with un gated high-pitch CT-angiography. *Sci Rep.* 2020;10(1):13909.

30. Andreassen C, Gislason GH, Kober L, et al. Incidence of ischemic stroke in individuals with and without aortic valve stenosis: a Danish retrospective cohort study. *Stroke.* 2020;51(5):1364-1371.

31. Flaherty ML, Kissela B, Khoury JC, et al. Carotid artery stenosis as a cause of stroke. *Neuroepidemiology.* 2013;40(1):36-41.

32. Wagner ML, Khoury JC, Alwell K, et al. Withdrawal of anti- thrombotic agents and the risk of stroke. *J Stroke Cerebrovasc Dis.* 2016;25(4):902-906.

33. Khalil AA, Villringer K, Fillebock V, et al. Non-invasive monitoring of longitudinal changes in cerebral hemodynamics in acute ischemic stroke using BOLD signal delay. *J Cereb Blood Flow Metab.* 2021;41(9):2280-2294.

34. Li S, Huang Y, Liu Y, et al. Change and predictive ability of circulatory immunoregulatory lymphocytes in long-term outcomes of acute ischemic stroke. *J Cereb Blood Flow Metab.* 2021;41(10):2617-2627.

35. Campbell BC. Ischaemic stroke. *Nat Rev Dis Primers.* 2019;5(1):1-22.

36. Menon U, Kenner M, Kelley RE. Perioperative stroke. *Expert Rev Neurother.* 2007;7(8):1003-1011.

37. Haupt M, Zeichmeister B, Bosche B, et al. Lithium enhances post-stroke blood-brain barrier integrity, activates the MAPK/
ERK1/2 pathway and alters immune cell migration in mice. Neuropharmacology, 2020;181:108357.
39. Arrarte Terreros N, van Willigen BG, Niekolaas WS, et al. Occult blood flow patterns distal to an occluded artery in acute ischemic stroke. J Cereb Blood Flow Metab. 2021;42(2):292-302.
40. Li M, Zhao Y, Zhan Y, et al. Enhanced white matter reorganization and activated brain glucose metabolism by enriched environment following ischemic stroke: micro PET/CT and MRI study. Neuropharmacology, 2020;176:108202.
41. Raghavendra Rao VL, Bowen KK, Dempsey RJ. Transient focal cerebral ischemia down-regulates glutamate transporters GLUT-1 and EAAC1 expression in rat brain. Neurochem Res. 2001;26(5):497-502.
42. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431-1567.
43. Tapeinos C, Larrañaga A, Tomatis F, et al. Advanced functional materials and cell-based therapies for the treatment of ischemic stroke and postischemic stroke effects. Adv Funct Mater. 2019;30(1):1906283.
44. Tuo QZ, Zhang ST, Lei P. Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Med Res Rev. 2021;42(1):259-305.
45. Wang J, Zhang W, Lv C, et al. A novel biscalcomarin compound ameliorates cerebral ischemia reperfusion-induced mitochondrial oxidative injury via Nrf2/Keap1/ARE signaling. Neuropharmacology, 2020;167:107918.
46. Davis SM, Pennypacker KR. Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke. Neurochem Int. 2017;107:23-32.
47. Pravalka K, Sarmah D, Kaur H, et al. Trigonelline therapy confers neuroprotection by reduced glutathione mediated myeloperoxidase expression in animal model of ischemic stroke. Life Sci. 2019;216:49-58.
48. Wang H, Wang Z, Wu Q, et al. Regulatory T cells in ischemic stroke. CNS Neurosci Ther. 2021;27(6):643-651.
49. Chen C, Huang T, Zhai X, et al. Targeting neutrophils as a novel therapeutic strategy after stroke. J Cereb Blood Flow Metab. 2021;41(9):2150-2161.
50. Clausen BH, Lambertsen KL, Babcock AA, et al. Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation. 2008;5:46.
51. Deng W, Mandeville E, Terasaki Y, et al. Transcriptomic characterization of microglia activation in a rat model of ischemic stroke. J Cereb Blood Flow Metab. 2020;40(1_suppl):S34-S48.
52. Attif F, Youssif S, Espinosa-Garcia C, et al. Post-ischemic stroke systemic inflammation: immunomodulation by progesterone and vitamin D hormone. Neuropharmacology, 2020;181:108327.
53. Zhang S. Microglial activation after ischaemic stroke. Stroke Vasc Neurol. 2019;4(2):71-74.
54. Xu S, Lu J, Shao A, et al. Glial cells: role of the immune response in ischemic stroke. Front Immunol. 2020;11:294.
55. Wimmer I, Zrzavy T, Lassmann H. Neuroinflammatory responses in experimental and human stroke lesions. J Neuroimmunol. 2018;323:10-18.
56. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci. 2006;7(1):65-74.
57. Bassi M, Santinello I, Bevilacqua A, et al. Nanotechnology: a big revolution from the small world. Urologia. 2013;80(1):46-55.
58. Zhang Y, Li M, Gao X, et al. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J Hematol Oncol. 2019;12(1):137.
59. Li C, Sun T, Jiang C. Recent advances in nanomedicines for the treatment of ischemic stroke. Acta Pharmaceutica Sinica B. 2021;11(7):1767-1788.
60. Sarmah D, Banerjee M, Datta A, et al. Nanotechnology in the diagnosis and treatment of stroke. Drug Discov Today. 2021;26(2):585-592.
61. Wong XY, Sena-Torralba A, Alvarez-Diduk R, et al. Nanomaterials for nanotheranostics: tuning their properties according to disease needs. ACS Nano. 2020;14(3):2585-2627.
62. Zhang F, Lin YA, Kannan S, et al. Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release. 2016;240:212-226.
63. Oswald M, Geissler S, Goepferich A. Targeting the central nervous system (CNS): a review of rabies virus-targeting strategies. Mol Pharm. 2017;14(7):2177-2196.
64. Ahmed S, Alhareth K, Mignet N. Advancement in nanogel formulations provides controlled drug release. Int J Pharm. 2020;584:119435.
65. Heng PWS. Controlled release drug delivery systems. Pharm Dev Technol. 2018;23(9):833.
66. Lushchekina SV, Masson P. Slow-binding inhibitors of acetylcholinesterase of medical interest. Neuropharmacology. 2020;177:108236.
67. Fan M, Geng S, Liu Y, et al. Nanocrystal technology as a strategy to improve drug bioavailability and antitumor efficacy for the cancer treatment. Curr Pharm Des. 2018;24(21):2416-2424.
68. Murthy A, Ravi PR, Kathuria H, et al. Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene. Int J Pharm. 2020;588:119731.
69. Wu C, Gong MQ, Liu BY, et al. Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance. Colloids Surf, B. 2017;149:250-259.
70. Xie J, Shen Z, Anraku Y, et al. Nanomaterial-based blood-brain barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491.
71. Guo X, Deng G, Liu J, et al. Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy. ACS Nano. 2018;12(8):8723-8732.
72. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target. 2009;17(8):564-574.
73. Da Silva-Candal A, Argibay B, Iglesias-Rey R, et al. Vectorized nanodelivery systems for ischemic stroke: a concept and a need. J Nanobiotechnology. 2017;15(1):30.
74. Zhang C, Ling CL, Pang L, et al. Direct macromolecular drug delivery to cerebral ischemia area using neutrophil-mediated nanoparticles. Theranostics. 2017;7(13):3260-3275.
75. Liu Y, Ai K, Ji X, et al. Comprehensive insights into the multi-antioxidative mechanisms of melanin nanoparticles and their application to protect brain from injury in ischemic stroke. J Am Chem Soc. 2017;139(2):856-862.
76. Han FY, Thurecht KJ, Whittaker AK, et al. Bioerodable PLGA-Based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Front Pharmacol. 2016;7:185.
77. Fuller EG, Scheutz GM, Jimenez A, et al. Theranostic nanocarriers combining high drug loading and magnetic particle imaging. Int J Pharm. 2019;572:118796.
78. Tian X, Fan T, Zhao W, et al. Recent advances in the development of nanomedicines for the treatment of ischemic stroke. Bioact Mater. 2021;6(9):2854-2869.
79. Guo W, Song Y, Song W, et al. Co-delivery of doxorubicin and curcumin with polypeptide nanocarrier for synergistic lymphoma therapy. Sci Rep. 2020;10(1):7832.
80. Park TE, Singh B, Li H, et al. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease. Biomaterials. 2015;38:61-71.
81. Maria Rita M, Rodolfo B, Alessandro M, et al. Lipid-based nano-carriers for CNS-targeted drug delivery. Recent Pat CNS Drug Discov. 2012;7(1):71-86.

82. Dong X, Gao J, Su Y, et al. Nanomedicine for ischemic stroke. Int J Mol Sci. 2020;21(20):7600.

83. Colasuonno M, Palange AL, Aid R, et al. Erythrocyte-inspired discoidal polymeric nanoconstructs carrying tissue plasminogen activator for the enhanced lysis of blood clots. ACS Nano. 2018;12(12):12224-12237.

84. Wang X, Wei C, Liu M, et al. Near-infrared triggered release of uPA from nanospheres for localized hyperthermia-enhanced thrombolysis. Adv Funct Mater. 2017;27(40):1701824.

85. Wan M, Wang Q, Wang R, et al. Platelet-derived porous nanomotor. Sci Adv. 2020;6:1-13.

86. Matrali SSH, Ghag AK. Feedback-controlled release of alendronate from composite microparticles. J Funct Biomater. 2020;11(3):46.

87. He L, Huang G, Liu H, et al. Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. Sci Adv. 2020;6(12):eaay9751.

88. Li S, Jiang D, Rosenkrans ZT, et al. Aptamer-conjugated framework nucleic acids for the repair of cerebral ischemia-reperfusion injury. Nano Lett. 2019;19(10):7334-7341.

89. Li S, Jiang D, Ehlerding EB, et al. Intrathecal administration of nanoclusters for protecting neurons against oxidative stress in cerebral ischemia/reperfusion injury. ACS Nano. 2019;13(11):13382-13389.

90. Wang H, Xu X, Guan X, et al. Liposomal 9-aminoacridine for treatment of ischemic stroke: from drug discovery to drug delivery. Nano Lett. 2020;20(3):1542-1551.

91. Lu Y, Li C, Chen Q, et al. Microthrombus-targeting micelles for neurovascular remodeling and enhanced microcirculatory perfusion in acute ischemic stroke. Adv Mater. 2019;31(21):1808361.

92. Tang C, Wang C, Zhang Y, et al. Recognition, intervention, and monitoring of neutrophils in acute ischemic stroke. Nano Lett. 2019;19(7):4470-4477.

93. Hu J, Huang S, Zhu L, et al. Tissue plasminogen activator-porous magnetic microrods for targeted thrombolytic therapy after ischemic stroke. ACS Appl Mater Interfaces. 2018;10(39):32988-32997.

94. Zhang T, Li F, Xu Q, et al. Ferrimagnetic nanochains-based mesenchymal stem cell engineering for highly efficient post-stroke recovery. Adv Funct Mater. 2019;29(24):1900603.

95. Kim HY, Kim TJ, Kang L, et al. Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke. Biomaterials. 2020;243:119942.

96. Zivin JA. Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and drug administration (FDA). Ann Neurol. 2009;66(1):6-10.

97. Zhang L, Chopp M, Jia L, et al. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab. 2009;29(11):1816-1824.

98. Daffertshofer M, Hennerici M. Ultrasound in the treatment of ischemic stroke. Lancet Neurol. 2003;2(5):283-290.

99. Khandelwal P, Yavagal DR, Sacco RL. Acute ischemic stroke intervention. J Am Coll Cardiol. 2016;67(22):2631-2644.

100. Xu J, Zhang Y, Xu J, et al. Engineered nanoplatelets for targeted delivery of plasminogen activators to reverse thrombus in multiple mouse thrombosis models. Adv Mater. 2020;32(4):e1905145.

101. Heckman KL, DeCoteau W, Estevez A, et al. Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. ACS Nano. 2013;7(12):10582-10596.

102. Estevez AY, Pritchard S, Harper K, et al. Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia. Free Radic Biol Med. 2011;51(6):1155-1163.

103. Cai M, Sun S, Wang J, et al. Sevoflurane preconditioning protects experimental ischemic stroke by enhancing anti-inflammatory microglia/macrophages phenotype polarization through GSK-3beta/Nrf2 pathway. CNS Neurosci Ther. 2021;27(11):1348-1365.

104. Petro M, Jaffer H, Yang J, et al. Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. Biomaterials. 2016;81:169-180.